Updated:
Aclaris Therapeutics
Aclaris is a biopharmaceutical company that strives to translate scientific discoveries into everyday victories in dermatology, and beyond. Learn about our...
Aclaris Therapeutics
Aclaris is a biopharmaceutical company that strives to translate scientific discoveries into everyday victories in dermatology, and beyond. Learn about our pipeline.
General information
Firm type
other
Location
Region
North America
Country
United States
City
Wayne
Corporate office
Wayne, PA, United States
Additional offices
4340 Duncan Avenue, Suite 400, St. Louis, MO, United States
Sector focus
Frequently asked questions
What is Aclaris Therapeutics' core investment focus?
Aclaris Therapeutics is a biopharmaceutical company focused on developing therapies for immuno-inflammatory conditions, particularly in dermatology. It aims to address underserved patient populations by translating scientific discoveries into treatments for areas with significant gaps, as described on its website.
Does Aclaris Therapeutics operate as a family office or asset manager?
No. Aclaris Therapeutics is a publicly traded biopharmaceutical company, not a family office or asset manager. It develops and commercializes therapies, distinct from investment management entities.
Where is Aclaris Therapeutics headquartered?
Aclaris Therapeutics' headquarters is located at 701 Lee Road, Suite 103, Wayne, Pennsylvania 19087, United States. It also maintains an office in St. Louis, Missouri, at 4340 Duncan Avenue, Suite 400, as listed on its contact page.
What therapeutic areas does Aclaris Therapeutics target?
Aclaris Therapeutics focuses on immuno-inflammatory conditions, with a primary emphasis on dermatology. The company targets 'white spaces'—underserved conditions where significant treatment gaps exist, as stated on its website.
Does Aclaris Therapeutics disclose its financial metrics such as AUM or deployment?
No. Aclaris Therapeutics has not publicly disclosed any AUM, deployment numbers, or financial metrics related to investment management. Its public communications focus on its pipeline and therapeutic innovation.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: